Inhibition of Bradykinin in COVID-19 Infection With Icatibant
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection.
Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation,
hypotension and cytokine release.